Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2018 | Original Article – Cancer Research

Risk for cancer in living kidney donors and recipients

Authors: Min Wang, Huai Zhang, Dan Zhou, Yong-Chao Qiao, Yan-Hong Pan, Yan-Chao Wang, Hai-Lu Zhao

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2018

Abstract

Objective

Malignancy following renal transplantation remains inconsistent with the reported safety of kidney donation during the long-term follow-up.

Methods

We conducted searches of the published literature which included healthy participants, recipients, living kidney donors (LKDs), and the availability of outcome data for malignancy. Eight from 938 potentially relevant studies were analyzed by means of fixed-effects model or random-effects model, as appropriately.

Results

In 48,950 participants, the follow-up range was 18 months to 20 years, and the mean age of the subjects was approximately 41 years. The incidence rate with 95% confidence interval (CI) for malignancy after kidney transplantation was 0.03 (0.01–0.05) in recipients and 0.03 (0.1–0.07) in LKDs, giving a pooled incidence rate of 0.03 (95% CI 0.02–0.04). LKDs contrasted nondonors by the overall odds ratio and 95% CI for total cancer of 2.80 (2.69–2.92).

Conclusions

Kidney transplantation was associated with an increased risk of cancer during a long-term follow-up. Long-term risk for cancer in LKDs and kidney recipients should be monitored.

Available only for authorised users

Arichi N, Kishikawa H, Nishimura K, Mitsui Y, Namba Y, Tokugawa S, Ichikawa Y (2008) Malignancy following kidney transplantation. Transplant Proc 40:2400–2402. https://doi.org/10.1016/j.transproceed.2008.07.103 CrossRefPubMed

Bernard WS, Christopher PW (2014) World cancer report 2014. France the international agency for research on cancer

Birkeland SA, Storm HH (2002) Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 74:1409–1413. https://doi.org/10.1097/01.TP.0000034717.19606.B5 CrossRefPubMed

Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, Rosas-Arellano MP, Housawi A, Garg AX, Donor Nephrectomy Outcomes Research, N (2006) Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 145:185–196CrossRefPubMed

Butt AQ, Mills KH (2014) Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 33:4623–4631. https://doi.org/10.1038/onc.2013.432 CrossRefPubMed

Byrne WL, Mills KH, Lederer JA, O’Sullivan GC (2011) Targeting regulatory T cells in cancer. Cancer Res 71:6915–6920. https://doi.org/10.1158/0008-5472.CAN-11-1156 CrossRefPubMedPubMedCentral

Chu KH, Poon CK, Lam CM, Cheuk A, Yim KF, Lee W, Tang HL, Chan HW, Fung KS, Tong KL (2012) Long-term outcomes of living kidney donors: a single centre experience of 29 years. Nephrology (Carlton) 17:85–88. https://doi.org/10.1111/j.1440-1797.2011.01524.x CrossRef

Davis CL (2009) Living kidney donors: current state of affairs. Adv Chronic Kidney Dis 16:242–249. https://doi.org/10.1053/j.ackd.2009.05.007 CrossRefPubMed

Gossmann J, Wilhelm A, Kachel HG, Jordan J, Sann U, Geiger H, Kramer W, Scheuermann EH (2005) Long-term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center. Am J Transpl 5:2417–2424. https://doi.org/10.1111/j.1600-6143.2005.01037.x CrossRef

Gupta NP, Albani JM, Novick AC, Sivaramakrishna B, Kumar R (2004) Renal cell cancer in solitary kidney after donor nephrectomy. Urology 64:808–809. https://doi.org/10.1016/j.urology.2004.05.015 CrossRefPubMed

Hew MN, Opondo D, Cordeiro ER, van Donselaar-van der Pant KA, Bemelman FJ, Idu MM, de la Rosette JJ, Laguna MP (2014) The 1-year decline in estimated glomerular filtration rate (eGFR) after radical nephrectomy in patients with renal masses and matched living kidney donors is the same. BJU Int 113:E49-55. https://doi.org/10.1111/bju.12345 CrossRefPubMed

Howard RJ, Reed AI, Van Der Werf WJ, Hemming AW, Patton PR, Scornik JC (2001) What happens to renal transplant recipients who lose their grafts? Am J Kidney Dis 38:31–35. https://doi.org/10.1053/ajkd.2001.25178 CrossRefPubMed

Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR, Matas AJ (2009) Long-term consequences of kidney donation. N Engl J Med 360:459–469. https://doi.org/10.1056/NEJMoa0804883 CrossRefPubMedPubMedCentral

Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transpl 4:905–913. https://doi.org/10.1111/j.1600-6143.2004.00450.x CrossRef

Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, Kumar R, Posselt AA, Pesavento TE, Rabb H, Steffes MW, Snyder JJ, Weir MR (2015) A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis 66:114–124. https://doi.org/10.1053/j.ajkd.2015.01.019 CrossRefPubMedPubMedCentral

Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66:408–414. https://doi.org/10.1016/j.jclinepi.2012.09.016 CrossRefPubMed

Lentine KL, Patel A (2012) Risks and outcomes of living donation. Adv Chronic Kidney Dis 19:220–228. https://doi.org/10.1053/j.ackd.2011.09.005 CrossRefPubMedPubMedCentral

Lentine KL, Vijayan A, Xiao H, Schnitzler MA, Davis CL, Garg AX, Axelrod D, Abbott KC, Brennan DC (2012) Cancer diagnoses after living kidney donation: linking USA Registry data and administrative claims. Transplantation 94:139–144. https://doi.org/10.1097/TP.0b013e318254757d CrossRefPubMedPubMedCentral

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Studies P, C (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913CrossRefPubMed

Li SS, Huang YM, Wang M, Shen J, Lin BJ, Sui Y, Zhao HL (2016). A meta-analysis of renal outcomes in living kidney donors. Medicine (Baltimore) 95:e3847. https://doi.org/10.1097/MD.0000000000003847

Mazuecos A, Munoz Terol JM, Garcia Alvarez T, Sola E, Rodriguez Benot A, Dsuna A, Bedoya R, Gentil MA (2009) Increase in malignancies as cause of death in renal transplant patients. Transplant Proc 41:2159–2162. https://doi.org/10.1016/j.transproceed.2009.05.029 CrossRefPubMed

Moray G, Basaran O, Yagmurdur MC, Emiroglu R, Bilgin N, Haberal M (2004) Immunosuppressive therapy and Kaposi’s sarcoma after kidney transplantation. Transplant Proc 36:168–170. https://doi.org/10.1016/j.transproceed.2003.11.016 CrossRefPubMed

Nafar M, Einollahi B, Hemati K, Gholi FP, Firouzan A (2005) Development of malignancy following living donor kidney transplantation. Transplant Proc 37:3065–3067. https://doi.org/10.1016/j.transproceed.2005.08.011 CrossRefPubMed

Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transpl 4:222–230CrossRef

Park JH, Park JH, Bok HJ, Kim BS, Yang CW, Kim YS, Kim SY, Moon IS, Koh YB, Bang BK (2000) Posttransplant malignancy during 30 years at a single center. Transpl Proc 32:1979

Peddi VR, Whiting J, Weiskittel PD, Alexander JW, First MR (1998) Characteristics of long-term renal transplant survivors. Am J Kidney Dis 32:101–106CrossRefPubMed

Robitaille P, Mongeau JG, Lortie L, Sinnassamy P (1985) Long-term follow-up of patients who underwent unilateral nephrectomy in childhood. Lancet 1:1297–1299CrossRefPubMed

Rostami Z, Einollahi B, Lessan-Pezeshki M, Nourbala MH, Nemati E, Pourfarziani V, Shahbazian H, Khosravi M, Jalalzadeh M (2011) Old male living renal transplant recipients more likely to be at risk for colorectal cancer. Transpl Proc 43:588–589. https://doi.org/10.1016/j.transproceed.2011.01.073 CrossRef

Schmidt R, Stippel D, Krings F, Pollok M (1995) Malignancies of the genito-urinary system following renal transplantation. Br J Urol 75:572–577CrossRefPubMed

Schold JD, Goldfarb DA, Buccini LD, Rodrigue JR, Mandelbrot DA, Heaphy EL, Fatica RA, Poggio ED (2013) Comorbidity burden and perioperative complications for living kidney donors in the United States. Clin J Am Soc Nephrol 8:1773–1782. https://doi.org/10.2215/CJN.12311212 CrossRefPubMedPubMedCentral

Schold JD, Goldfarb DA, Buccini LD, Rodrigue JR, Mandelbrot D, Heaphy EL, Fatica RA, Poggio ED (2014) Hospitalizations following living donor nephrectomy in the United States. Clin J Am Soc Nephrol 9:355–365. https://doi.org/10.2215/CJN.03820413 CrossRefPubMedPubMedCentral

Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, McBride MA, Montgomery RA (2010) Perioperative mortality and long-term survival following live kidney donation. JAMA 303:959–966. https://doi.org/10.1001/jama.2010.237 CrossRefPubMed

Shen J, Huang YM, Song XN, Hong XZ, Wang M, Ling W, Zhang XX, Zhao HL (2016a). Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin Angiotensin Aldosterone Syst. https://doi.org/10.1177/1470320316656481

Shen J, Huang YM, Wang M, Hong XZ, Song XN, Zou X, Pan YH, Ling W, Zhu MH, Zhang XX, Sui Y, Zhao HL (2016b). Renin-angiotensin system blockade for the risk of cancer and death. J Renin Angiotensin Aldosterone Syst. https://doi.org/10.1177/1470320316656679

Spital A (2015) Regarding ‘Long-term risks for kidney donors’. Kidney Int 87:660. https://doi.org/10.1038/ki.2014.397 CrossRefPubMed

Srinivas TR, Poggio ED (2012) Do living kidney donors have CKD? Adv Chronic Kidney Dis 19:229–236. https://doi.org/10.1053/j.ackd.2012.05.008 CrossRefPubMed

Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P (2012) Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 59:802–810. https://doi.org/10.1161/HYPERTENSIONAHA.111.189258 CrossRefPubMed

Strauss DC, Thomas JM (2010) Transmission of donor melanoma by organ transplantation. Lancet Oncol 11:790–796. https://doi.org/10.1016/S1470-2045(10)70024-3 CrossRefPubMed

Sui Y, Zhao HL, Ma RC, Ho CS, Kong AP, Lai FM, Ng HK, Rowlands DK, Chan JC, Tong PC (2007) Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. Cell Mol Life Sci 64:3119–3128. https://doi.org/10.1007/s00018-007-7395-1 CrossRefPubMed

Sui Y, Zhao HL, Lee HM, Guan J, He L, Lai FM, Tong PC, Chan JC (2009) Renal carcinogenesis after uninephrectomy. Transl Oncol 2:258–263CrossRefPubMedPubMedCentral

Sui Y, Zhao HL, Fan RR, Guan J, He L, Lee HM, Chan JC, Tong PC (2010) Renin-angiotensin system activation in renal adipogenesis. Am J Physiol Renal Physiol 298:F391-400. https://doi.org/10.1152/ajprenal.00445.2009 CrossRefPubMed

Veroux M, Puliatti C, Fiamingo P, Cappello D, Macarone M, Puliatti D, Vizcarra D, Gagliano M, Veroux P (2004) Early de novo malignancies after kidney transplantation. Transpl Proc 36:718–720. https://doi.org/10.1016/j.transproceed.2004.03.021 CrossRef

Yan L, Chen P, Chen EZ, Gu A, Jiang ZY (2014) Risk of bladder cancer in renal transplant recipients: a meta-analysis. Br J Cancer 110:1871–1877. https://doi.org/10.1038/bjc.2014.44 CrossRefPubMedPubMedCentral

Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H, Luk AO, Lam CW, Ho CS, Tong PC, Chan JC (2009a) Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 32:1826–1832. https://doi.org/10.2337/dc09-0725 CrossRefPubMedPubMedCentral

Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, Kong AP, Ozaki R, Yeung CY, Xu G, Tong PC, Chan JC (2009b) Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58:1518–1525. https://doi.org/10.2337/db09-0105 CrossRefPubMedPubMedCentral

Yang KK, Sui Y, Zhou HR, Shen J, Tan N, Huang YM, Li SS, Pan YH, Zhang XX, Zhao HL (2016). Cross-talk between AMP-activated protein kinase and renin-angiotensin system in uninephrectomised rats. J Renin Angiotensin Aldosterone Syst. https://doi.org/10.1177/1470320316673231

Yang KK, Sui Y, Zhou HR, Zhao HL (2017). Interaction of renin-angiotensin system and adenosine monophosphate-activated protein kinase signaling pathway in renal carcinogenesis of uninephrectomized rats. Tumour Biol 39:1010428317699116. https://doi.org/10.1177/1010428317699116

Zhao HL, Sui Y, Guan J, He L, Zhu X, Fan RR, Xu G, Kong AP, Ho CS, Lai FM, Rowlands DK, Chan JC, Tong PC (2008) Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int 74:467–477. https://doi.org/10.1038/ki.2008.195 CrossRefPubMed

Zhao HL, Sui Y, He L, Guan J, Xiao SJ, Zhong DR, Xu Q, Zeng SE (2011) Lipid partitioning after uninephrectomy. Acta Diabetol 48:317–328. https://doi.org/10.1007/s00592-011-0286-9 CrossRefPubMed

Title: Risk for cancer in living kidney donors and recipients
Authors: Min Wang
Huai Zhang
Dan Zhou
Yong-Chao Qiao
Yan-Hong Pan
Yan-Chao Wang
Hai-Lu Zhao
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2590-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model

High nuclear MSK1 is associated with longer survival in breast cancer patients

Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma

CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation

A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma

Ecto-5′-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage